Optimizing the In Vivo Approach: Considerations for Safety & Tolerability
Time: 1:30 pm
day: Day 2, Track A pm
• How do we improve the safety and tolerability of in vivo therapies?
• To what extent do we have to worry about off-target effects?
• How do we circumnavigate the issue of immunogenicity and integration?